Page 5 - Journal of Structural Heart Disease Volume 4, Issue 3

MelodyTM Transcatheter Pulmonary Valve, EnsembleTM II Transcatheter Valve Delivery System
Important Labeling Information for the United States
Indications
The Melody TPV is indicated for use in the management of pediatric and adult patients who have a clinical indication for intervention on a dysfunctional right ventricular out ow tract (RVOT) conduit or surgical bioprosthetic pulmonary valve that has ≥ moderate regurgitation, and/or a mean RVOT gradient
≥ 35 mm Hg.
Contraindications
None known
Warnings/Precautions/Side E ects
DO NOT implant in the aortic or mitral position. Pre-clinical bench testing of the Melody valve suggests that valve function and durability will be extremely limited when used in these locations.
DO NOT use if patient’s anatomy precludes introduction of the valve, if the venous anatomy cannot accommodate a 22 Fr size introducer, or if there is signi cant obstruction of the central veins.
DO NOT use if there are clinical or biological signs of infection including active endocarditis. Standard medical and surgical care should be strongly considered in these circumstances.
Assessment of the coronary artery anatomy for the risk of coronary artery compression should be performed in all patients prior to deployment of the TPV.
To minimize the risk of conduit rupture, do not use a balloon with a diameter greater than 110% of the nominal diameter (original implant size) of
the conduit for pre-dilation of the intended site of deployment, or for deployment of the TPV.
The potential for stent fracture should be considered in all patients who undergo TPV placement. Radiographic assessment of the stent with chest radiography or uoroscopy should be included in the routine postoperative evaluation of patients who receive a TPV.
If a stent fracture is detected, continued monitoring of the stent should be performed in conjunction with clinically appropriate hemodynamic assessment. In patients with stent fracture and signi cant associated RVOT obstruction or regurgitation, reintervention should be considered in accordance with usual clinical practice.
Potential procedural complications that may result from implantation of the Melody device include the following: rupture of the RVOT conduit, compression of a coronary artery, perforation of a major blood vessel, embolization or migration of the device, perforation of a heart chamber, arrhythmias, allergic reaction to contrast media, cerebrovascular events (TIA, CVA), infection/ sepsis, fever, hematoma, radiation-induced erythema, blistering, or peeling
of skin, pain, swelling, or bruising at the catheterization site.
Potential device-related adverse events that may occur following device implantation include the following: stent fracture*, stent fracture resulting in recurrent obstruction, endocarditis, embolization or migration of the device, valvular dysfunction (stenosis or regurgitation), paravalvular leak, valvular thrombosis, pulmonary thromboembolism, hemolysis.
*The term “stent fracture” refers to the fracturing of the Melody TPV. However, in subjects with multiple stents in the RVOT it is di cult to de nitively attribute stent fractures to the Melody frame versus another stent.
For additional information, please refer to the Instructions for Use provided with the product or available on http://manuals.medtronic.com.
CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician.
Important Labeling Information
for Geographies Outside of the United States
Indications
The MelodyTM TPV is indicated for use in patients with the following clinical conditions:
Patients with regurgitant prosthetic right ventricular out ow tract (RVOT) conduits or bioprostheses with a clinical indication for invasive or surgical intervention, OR
Patients with stenotic prosthetic RVOT conduits or bioprostheses where the risk of worsening regurgitation is a relative contraindication to balloon dilatation or stenting
Contraindications
Venous anatomy unable to accommodate a 22 Fr size introducer sheath Implantation of the TPV in the left heart
RVOT unfavorable for good stent anchorage
Severe RVOT obstruction, which cannot be dilated by balloon Obstruction of the central veins
Clinical or biological signs of infection Active endocarditis
Known allergy to aspirin or heparin Pregnancy
Potential Complications/Adverse Events: Potential procedural complications that may result from implantation of the Melody device include the following: rupture of the RVOT conduit, compression of a coronary artery, perforation of
a major blood vessel, embolization or migration of the device, perforation of a heart chamber, arrhythmias, allergic reaction to contrast media, cerebrovascular events (TIA, CVA), infection/sepsis, fever, hematoma, radiation-induced erythema, pain, swelling or bruising at the catheterization site.
Potential device-related adverse events that may occur following device implantation include the following: stent fracture*, stent fracture resulting in recurrent obstruction, endocarditis, embolization or migration of the device, valvular dysfunction (stenosis or regurgitation), paravalvular leak, valvular thrombosis, pulmonary thromboembolism, hemolysis.
*The term “stent fracture” refers to the fracturing of the Melody TPV. However, in subjects with multiple stents in the RVOT it is di cult to de nitively attribute stent fractures to the Melody frame versus another stent.
For additional information, please refer to the Instructions for Use provided with the product or available on http://manuals.medtronic.com.
The Melody Transcatheter Pulmonary Valve and Ensemble II Transcatheter Delivery System has received CE Mark approval and is available for distribution in Europe.
©2018 Medtronic. All rights reserved. UC201808777 EN 03/2018